Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

doi:10.1200/JCO.2008.17.4284

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Nov 2008

Heinrich Michael C, Owzar Kouros, Corless Christopher L, Hollis Donna, Borden Ernest C, Fletcher Christopher D M, Ryan Christopher W, von Mehren Margaret, Blanke Charles D, Rankin Cathryn, Benjamin Robert S, Bramwell Vivien H, Demetri George D, Bertagnolli Monica M, Fletcher Jonathan A

Abstract excerpt

PURPOSE: Imatinib mesylate is standard treatment for patients who have advanced gastrointestinal stromal tumor (GIST), but not all patients benefit equally. In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing. PATIENTS AND METHODS: We examined the rela...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 18955451
DOI: 10.1200/JCO.2008.17.4284
PMCID: PMC2651078

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18955451-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.PMID 18955451Read ↗

Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.Semantic proximity Read ↗

Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.Semantic proximity Read ↗

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.Semantic proximity Read ↗

Impact of Mutation Profile on Outcomes of Neoadjuvant Therapy in GISTSemantic proximity Read ↗

Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder?Semantic proximity Read ↗

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.Semantic proximity Read ↗

KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment.Semantic proximity Read ↗

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial.Semantic proximity Read ↗

Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.